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Letters
To the Editor:
The recent articles by Khaja, et al (1) and Anderson, et al
(2) constitute a significant contribution to the experience with thrombolytic therapy in the management of
acute evolving myocardial infarction. However, other
reports consistent with these trials yielded disparate
results and conclusions. The data presented by Anderson, et al (2) suggest favorable effects of streptokinase,
but there are methodological problems: inclusion of
subjects w h o had subtotal occlusion o f t h e infarct artery,
and random assignment of control patients to routine
cardiac care unit management w i t h o u t angiographic
characterization of coronary anatomy. In an accompanying editorial (3), Swan suggests that the time interval
between the onset of chest pain and intervention w i t h
streptokinase may be the critical variable to explain the
seemingly inconsistent findings in these t w o studies. This
suggestion, which has been made previously (4), seems
to be inconsistent with reports that streptokinase therapy is effective after mean times of 5.6 ± 4 hours (5) and
9.2 ± 4 hours (6).
Comparison with results f r o m previous investigations is
complicated by the use of different doses, routes, and
times of administration of streptokinase (5-8), varied
usage and modes of administration of anticoagulant
therapy (5-8) and by occasional use of corticosteroids
and plasminogen (7). Earlier trials lacked randomization
and prospective controls (5-7); however, in even more
recent studies selected patient groups were so dissimilar
that valid comparisons were impossible.
An association has been demonstrated between spasm
and the site of significant coronary stenoses (9). How
does this observation relate to subjects w i t h total versus
subtotal coronary occlusion?

experimental animal studies (10) and in humans (11).
That this phenomenon may promote delayed infarct
healing, increase susceptibility to rupture and aneurysm
f o r m a t i o n , and lead to infarct extension (10) merits concern (12). Could streptokinase be replacing an ischemic,
" b l a n d " infarct with a hemorrhagic one? If so, w o u l d it
account for the absence of benefit in ventricular function after therapy?
Streptokinase is an effective agent for producing reperfusion t h r o u g h an occluded infarct artery. Its effect on
the ischemic myocardium, however, is less well established. Identifying the clinical, laboratory, and angiographicfeatures of patients likely t o benefit f r o m t h r o m bolytic therapy is essential. O n l y rigorously designed,
randomized trials with standardized protocols will resolve
these crucial questions: Can streptokinase favorably
influence infarct size w i t h o u t unnecessary potential risk?
If so, what is its optimal t i m i n g and route of administration? What other therapeutic agents (e.g., nitrates, betablockers, calcium antagonists, anti-platelet drugs) can be
combined with streptokinase for additional benefit?
What are the long-term effects of successful reperfusion; and are there definite end-points indicating advantage or detriment? After successful reperfusion, what
f o r m of management is best to treat the remaining coronary artery disease? What is the optimal time for such
intervention?
W e agree with the dictum of Leroy and Snider (13) that
"suspicion rather than certainty should govern the physician's c o n d u c t . " Widespread application of t h r o m b o lytictherapy to acute myocardial infarction should await
further demonstration of its unequivocal benefit.
David M . Lang, M D
Jan Rival, M D
Department of internal Medicine,
Henry Ford Hospital

The occurrence of hemorrhagic myocardial infarction
after successful reperfusion has been described both in
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